Similar Items: Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
- Potential of oncolytic viruses in the treatment of multiple myeloma
- The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities
- Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
- Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
- Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma
- Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma